ZP
IMNM icon

Zimmer Partners’s Immunome IMNM Stock Holding History

Zimmer Partners’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100,000
Closed -$673K – 189
2025
Q1 		$673K Buy
+100,000
New +$959K 0.01% 166
2024
Q3 		– Sell
-75,000
Closed -$908K – 165
2024
Q2 		$908K Hold
75,000
– – 0.02% 140
2024
Q1 		$1.85M Buy
+75,000
New +$1.52M 0.04% 114

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Zimmer Partners's IMNM Position: Q2 2025 in Review

Zimmer Partners sold out of Immunome (IMNM) in Q2 2025, closing a stake of 100,000 shares — an estimated $673K sold.

Zimmer Partners first reported a position in IMNM in Q1 2024 and held it in 3 quarters. The position peaked at $1.85M in Q1 2024. 142 funds tracked by Wall St. Rank hold IMNM as of Q2 2025.

  • Zimmer Partners reported no remaining Immunome position as of Q2 2025 after selling out during the quarter.
  • Zimmer Partners sold 100,000 Immunome shares in Q2 2025, an estimated $673K.
  • Zimmer Partners first reported a position in Immunome in Q1 2024 and held it in 3 quarters.
  • Zimmer Partners's Immunome position peaked at $1.85M in Q1 2024.
  • 142 funds tracked by Wall St. Rank held Immunome as of Q2 2025.

Based on Zimmer Partners's 13F filing for Q2 2025, filed 14 Aug 2025.